Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Free Trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Free Trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical productsRead more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Free Trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Sonia Corrent · Director General, Health Canada (HC)
Maria Sultan-Khan · Senior advisor, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Supriya Sharma · Acting Assistant Deputy Minister, Health Canada (HC)
Scott Lohnes · Senior advisor, Health Canada (HC)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Free Trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
and 6 moreShow fewer
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
Free Trade agreements as they relate to the biopharmaceutical industryRead more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
and 6 moreShow fewer
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulationsRead more
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
and 3 moreShow fewer
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Policy Advisor, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.Read more
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.Read more
Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Free Trade agreements as they relate to the biopharmaceutical industry
Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
and 6 moreShow fewer
Justine Frame · Policy Advisor, Health Canada (HC)
Linsey Hollett · Assistant deputy Minister, Health Canada (HC)
Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Rodrigo Arancibia · Director General, Innovation, Science and Economic Development Canada (ISED)
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Free Trade agreements as they relate to the biopharmaceutical industry
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Free Trade agreements as they relate to the biopharmaceutical industry
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Jibril Hussein · Senior Policy Advisor, Health Canada (HC)
Justine Frame · Policy advisor, Health Canada (HC)
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.Read more
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Justine Frame · Policy advisor, Health Canada (HC)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Special Assistant, Policy, Health Canada (HC)
Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Free Trade agreements as they relate to the biopharmaceutical industry
Policy measures to ensure security of
drug supply in Canada and preserve
Canada's attractiveness for
biopharmaceutical launches, including
in response to foreign pricing
regulations.
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Steven Sternthal · Director General, Public Health Agency of Canada (PHAC)
Semhar Zerat · Director, Public Health Agency of Canada (PHAC)
Fonju Ndemesah · Senior Policy Analyst, Public Health Agency of Canada (PHAC)
Tanya Lary · Director, Public Health Agency of Canada (PHAC)
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.Read more
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Maggie Chi · Parliamentary Secretary, Health Canada (HC)
Justine Frame · Special Assistant, Policy, Health Canada (HC)
Nora Draper · Parliamentary Secretary Assistant, Health Canada (HC)
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Kyle Allen · Director of Communications, Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC)
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.Read more
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Justine Frame · Special Assistant, Policy, Health Canada (HC)
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Policy and Programs
Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Sandenga Yeba · Director of Policy and Deputy Chief of Staff, Health Canada (HC)
Justine Frame · Special Assistant, Policy, Health Canada (HC)
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.Read more
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Federal Government First Nations and Inuit Health Branch program with respect to health services. Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Karim Bardeesy · Parliamentary Secretary, Innovation, Science and Economic Development Canada (ISED)
Chase Knight · Parliamentary Secretary Assistant, Innovation, Science and Economic Development Canada (ISED)
Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Victoria Morton · Senior Communications Advisor, House of Commons
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
Canada Agency for Drugs and Technologies in Health (CADTH) as it relates to health economics assessment and recommendations made on new medicines.
Greg Orencsak · Deputy Minister, Health Canada (HC)
Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sectorRead more
Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations
Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026.
Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month.
Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means.
Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence.
PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.